In chronic lymphocytic leukemia (CLL), the inactivation of DUSP1/6 by BCI increases hyper-activation of the MAPK signaling cascade and modulates CLL death; however, the cell death is low in malignant B cell lymphoma cells or healthy donor-derived B cells, indicating that BCI, by targeting DUSP1/6, activates an immune response in CLL,163 suggesting that targeting DUSP1 may be beneficial in clinical trials. Here, DUSP1 is linked to B-cell non-Hodgkin lymphoma.